Colorcon Partners in Product Authentication Technology
By

By
Colorcon, an excipient manufacturer, and Applied DNA Sciences, a Stony Brook, New York-headquartered molecular-based authentication service provider, have signed a memorandum of understanding (MOU) to combine Applied DNA’s molecular taggant…

MilliporeSigma, bluebird bio Partner for Viral Vector Mfg
By

By
MilliporeSigma has signed a commercial supply agreement to manufacture viral vectors for bluebird bio, a Cambridge, Massachusetts-based clinical-stage gene therapy company, for its use in gene therapies. Under the multi-year…

BMS, Taris in Bladder Cancer Clinical Trial Pact
By

By
Bristol-Myers Squibb (BMS) and Taris Biomedical, a Lexington, Massachusetts-headquartered clinical-stage biopharmaceutical company, have entered into a clinical trial collaboration to evaluate the combination of Taris’ investigational product, TAR-200 (GemRIS), in…

Biogen, Ionis Partner for Antisense Oligonucleotide Therapies
By

By
Biogen and Ionis Pharmaceuticals, a Carlsbad, California-based pharmaceutical company, have entered into a collaboration to identify new antisense oligonucleotide drug candidates for treating spinal muscular atrophy (SMA). Biogen will have…

BI, Roche in Oligonucleotide Pact
By

By
Boehringer Ingelheim (BI) and Roche have signed a pact to focus on discovering and developing orally available locked nucleic acid oligonucleotides for treating inflammatory bowel diseases. Under the agreement, BI…

BI, Evox Therapeutics in RNA Drug-Delivery Pact
By

By
Boehringer Ingelheim (BI) has signed a research collaboration with Evox Therapeutics, an Oxford, UK-headquartered therapeutics company, to investigate exosome-mediated delivery of RNAs with medical relevance to targets for disease areas…

Allergan Appoints EVP, Global Operations
By

By
Allergan has appointed Wayne Swanton, currently senior vice president, global operations of the company, to executive vice president (EVP), global operations following notification that Rob Stewart, EVP and chief operating…

Takeda, Pfizer End Distribution Pact in Japan for Arthritis Drug Xeljanz
By

By
Pfizer Japan and Takeda Pharmaceutical Company plan to terminate co-promotion of Pfizer’s Xeljanz (tofacitinib citrate) 5-mg tablets, an oral Janus kinase inhibitor for treating rheumatoid arthritis, in Japan, effective March…

BI, Autifony Therapeutics in $742-Million CNS Drug Pact
By

By
Boehringer Ingelheim (BI) and Autifony Therapeutics, a Verona, Italy-headquartered spin-out from GlaxoSmithKline, have signed an agreement for acquiring certain aspects of Autifony’s voltage-gated potassium channel modulator platform. BI has obtained…

EMA OKs Samsung BioLogics Biomanufacturing Facility
By

By
The European Medicines Agency (EMA) has licensed a 150,000-liter biomanufacturing facility of Samsung BioLogics, an Incheon, Korea-based contract biologics manufacturer. The plant, which was approved for monoclonal antibody production, was…